Daehwa Pharmaceutical’s Liporaxel Sol. (ingredient: paclitaxel), a treatment for advanced, metastatic and local recurrent gastric cancer, has neared winning the health insurance coverage.
Three other drugs also obtained the health insurance review agency’s nod to grant reimbursement. They are Novartis Korea’s allergic asthma treatment Xolair Inj./Xolair Prefilled Syringe Inj. (omalizumab), AbbVie Korea’s moderate to severe plaque psoriasis treatment Skyrizi (risankizumab), and Lilly Korea’s breast cancer drug Verzenio Tab. (abemaciclib).
The Health Insurance Review and Assessment Service (HIRA)’s Pharmaceutical Reimbursement Review Committee recently held a meeting to review the four treatments.
The committee decided that the three products -- Xolair Inj./Xolair Prefilled Syringe Inj. 75, 100, Skyrizi Prefilled Syringe Inj., and Verzenio Tab. 50, 100, 150 mg – were valid for health insurance coverage.
However, the committee said it would grant reimbursement for Liporaxel 50mg/5mL, 0.1g/10mL, and 0.3g/30mL on the condition that Daehwa Pharmaceutical accepts the drug price that the committee suggested.
The HIRA’s final decision is subject to change in the event of changes in the specified reimbursement range, the standard items, changes in approval conditions of the drugs, or revocation of the drug license.
<© Korea Biomedical Review, All rights reserved.>